Key Points
- Director Brian Slingsby sold 104,320 Mineralys Therapeutics shares at an average price of $28.81, generating approximately $3.01 million; his remaining stake totals 7.81 million shares.
- MLYS shares opened at $25.86, with the company valued at about $2.29 billion. Mineralys recently reported an adjusted loss of $2.85 per share, substantially worse than the $0.55 consensus estimate.
- Institutional investors own 84.46% of the stock, while analysts maintain a consensus “Moderate Buy” rating with a $48.80 price target.
Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Get Free Report) Director Brian Slingsby sold 104,320 shares of the stock in a transaction that occurred on Tuesday, September 22nd. The shares were sold at an average price of $28.81, for a total transaction of $3,005,459.20. Following the completion of the transaction, the director owned 7,805,718 shares in the company, valued at $224,882,735.58. This represents a 1.32% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Mineralys Therapeutics Stock Down 2.7%
MLYS stock opened at $25.86 on Friday. The stock has a market cap of $2.29 billion, a P/E ratio of -6.10 and a beta of 0.68. The company has a current ratio of 34.46, a quick ratio of 34.46 and a debt-to-equity ratio of 0.18. Mineralys Therapeutics, Inc. has a twelve month low of $22.30 and a twelve month high of $47.65. The company's 50 day moving average is $27.14 and its two-hundred day moving average is $27.09.
Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its earnings results on Wednesday, August 12th. The company reported ($2.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($2.30). Research analysts expect that Mineralys Therapeutics, Inc. will post -4.45 earnings per share for the current fiscal year.
Institutional Trading of Mineralys Therapeutics
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Mineralys Therapeutics during the 2nd quarter worth $158,832,000. Bank of America Corp DE acquired a new position in Mineralys Therapeutics in the second quarter valued at $40,620,000. Orbimed Advisors LLC raised its holdings in shares of Mineralys Therapeutics by 109.4% in the first quarter. Orbimed Advisors LLC now owns 2,052,900 shares of the company's stock valued at $55,613,000 after buying an additional 1,072,500 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Mineralys Therapeutics in the second quarter valued at about $22,136,577. Finally, Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. acquired a new stake in shares of Mineralys Therapeutics during the fourth quarter worth about $23,918,000. Institutional investors and hedge funds own 84.46% of the company's stock.
Analyst Ratings Changes
Several research firms have issued reports on MLYS. Wall Street Zen downgraded shares of Mineralys Therapeutics from a "sell" rating to a "strong sell" rating in a research note on Saturday, August 15th. Zacks Research upgraded Mineralys Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Friday, September 11th. Weiss Ratings reissued a "sell (d-)" rating on shares of Mineralys Therapeutics in a report on Friday, July 17th. Jefferies Financial Group reissued a "hold" rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. Finally, HC Wainwright restated a "buy" rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Five research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Mineralys Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $48.80.
Read Our Latest Report on Mineralys Therapeutics
About Mineralys Therapeutics
(
Get Free Report)
Mineralys Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and kidney-related diseases. The company's research is centered on conditions associated with excess aldosterone activity, including uncontrolled and resistant hypertension.
Mineralys' lead investigational product is lorundrostat, also known as MLS-101, an oral, highly selective aldosterone synthase inhibitor. The company is evaluating lorundrostat in clinical studies as a potential treatment for patients whose blood pressure remains inadequately controlled despite existing therapy.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
